Induction therapy for clinical intestinal transplantation: comparison of four different regimens.
Pinna
A D
AD
Department of Surgery, Division of Transplantation, University of Miami School of Medicine, Miami, Florida 33101-5809, USA.
Weppler
D
D
Nery
J R
JR
Khan
F
F
Ruiz
P
P
Kato
T
T
De Faria
W
W
Berho
M
M
Tzakis
A G
AG
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003520:Cyclophosphamide / Q000627:therapeutic use; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000453:epidemiology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007422:Intestines / Q000637:transplantation*; D016031:Liver Transplantation / Q000401:mortality / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous / Q000276:immunology / Q000401:mortality / Q000502:physiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003520:Cyclophosphamide; D000077561:Daclizumab; D009173:Mycophenolic Acid